Summary:
In patients with type 2 diabetes, enavogliflozin, a selective SGLT2 inhibitor
significantly improved leptin levels, insulin resistance, and increased serum ketone levels compared to baseline or no enavogliflozin treatment, though it was associated with mild adverse effects related to metabolic parameters.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes who were inadequately controlled and had elevated leptin and insulin resistance levels. |
| Intervention | Treatment with enavogliflozin, a selective sodium-glucose co-transporter-2 (SGLT2) inhibitor, over 24 weeks. |
| Comparison | Baseline metabolic and glycemic parameters or no enavogliflozin treatment. |
| Outcome | Enavogliflozin significantly decreased leptin levels independent of weight changes, improved insulin resistance, and increased serum ketone levels. Treatment demonstrated potential benefits in managing metabolic dysregulation in addition to glycemic control. |
Source: Young Sang Lyu, et al. “Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.” Read article here.
